Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study
Imunologia e AlergiaResumo original em inglês
O que aconteceu
A short-course pre-seasonal subcutaneous injection of PQ Grass is clinically effective for the treatment of allergic rhinitis, though its mechanism remains unclear. The aim of the study was to interrogate immunological mechanisms induced by PQ Grass conventional and extended regimens.
A RDBPC exploratory field study involving participants that either received injections of PQ Grass with a cumulative dose of 27,600 SU conventional (six once weekly injections) or extended regimen (three once weekly injections followed by three once monthly injections) or placebo containing microcrystalline tyrosine (MCT) (placebo + MCT) or saline (placebo) was performed. Humoral, cellular, and molecular responses were assessed at baseline (V1), end of treatment, prior to grass pollen season (V12) and end of pollen season (V15). Immunoglobulin analyses and cellular/gene microarray analyses were performed in the sub-study cohort consisting of PQ Grass Conventional (n = 25 and n = 10, respectively), PQ Grass Extended (n = 26 and n = 10, respectively), Placebo with MCT (n = 13 and n = 5, respectively), and Placebo (saline; n = 12 and n = 5, respectively).
Trial number: PQGrass309, EudraCT number: 2020-000408-13, Clinicaltrials.gov identifier: NCT04687059, and NCT05540717.
O que encontraram
Both PQ Grass regimens, conventional and extended, were associated with improvement in total combined scores (TCS) with a relative difference of -35.0% (p = 0.03) and -40.8% (p = 0.01) against placebo with MCT, respectively. Both PQ Grass treatment regimens were associated with increases in the sIgG4/sIgE ratio (all, p < 0.05) and induction of IgA1 (all, p < 0.05) and IgA2 (all, p < 0.01) compared to placebo groups. Nasal fluid (p < 0.01) and serum (p < 0.05) blocking antibodies are functional and have the capacity to inhibit allergen-IgE complex formation and binding to B cells in the PQ Grass groups. In vitro cellular and microarray gene analyses demonstrated that the extended PQ Grass regimen was more proficient in modulating the immune response towards a tolerogenic milieu by dampening pro-inflammatory type 2 immune response and the associated cytokines (p < 0.05), immune deviation towards a Th1 response (p < 0.05), and induction of FOXP3+ Treg cells (p < 0.05).
Por que isso importa
For the first time, we highlight differential mechanisms of tolerance induction by PQ Grass, with the extended regimen being superior in modulating T cell compartments.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study
Janice A Layhadi, Sviatlana Starchenka, Pieter-Jan De Kam, Elizabeth Palmer, Lily Y D Wu, Sean T Keane, William T Fulton, Prista Hikmawati, Xun Meng, Paulina Filipaviciute et al.
Descritores MeSH
- Allergens
- Poaceae
- Immunity, Cellular
- Rhinitis, Allergic, Seasonal
- Immunity, Humoral
- Adult
- Male
- Middle Aged
- Pollen
- Treatment Outcome
Veja também
Estudos relacionados
- Análise bivariada dos tamanhos de efeito de sintomas e escores de medicamentos na imunoterapia de pólen de gramínea revela dissociação rota-dependente: implicações para o escore combinado de sintomas e medicamentos
- Comparative Efficacy of Subcutaneous and Sublingual Allergen Immunotherapy for Grass Pollen-Induced Allergic Rhinoconjunctivitis: Pairwise and Adjusted Indirect Treatment Comparison of Standardized ALK Products
- Grass pollen allergoids conjugated with mannan for subcutaneous and sublingual immunotherapy: a dose-finding study
- Nasal allergen-neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis